[go: up one dir, main page]

WO2001028570A3 - Zinc lactate lozenges and uses thereof - Google Patents

Zinc lactate lozenges and uses thereof Download PDF

Info

Publication number
WO2001028570A3
WO2001028570A3 PCT/GB2000/003990 GB0003990W WO0128570A3 WO 2001028570 A3 WO2001028570 A3 WO 2001028570A3 GB 0003990 W GB0003990 W GB 0003990W WO 0128570 A3 WO0128570 A3 WO 0128570A3
Authority
WO
WIPO (PCT)
Prior art keywords
lozenges
zinc
zinc lactate
lozenge
saliva
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/003990
Other languages
French (fr)
Other versions
WO2001028570A2 (en
Inventor
George Ferdinand Rowland
Kok Swee Foo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AZN BIOTECH Ltd
Original Assignee
AZN BIOTECH Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AZN BIOTECH Ltd filed Critical AZN BIOTECH Ltd
Priority to AU78089/00A priority Critical patent/AU7808900A/en
Publication of WO2001028570A2 publication Critical patent/WO2001028570A2/en
Publication of WO2001028570A3 publication Critical patent/WO2001028570A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

A lozenge, for release of zinc 2+ ions in the oral cavity of a human comprises 0.5 to 5 % by wt of zinc lactate in combination with a pharmaceutically acceptable carrier or sugar. In the presence of human saliva, said lozenge releases at least 0.2 mg of zinc 2+ ions per ml of saliva with a pleasant taste and aftertaste. The lozenges may be used as medicaments or nutritional supplements for reducing the symptoms and/or duration of the common cold, rhinitis and/or sinusitis.
PCT/GB2000/003990 1999-10-20 2000-10-18 Zinc lactate lozenges and uses thereof Ceased WO2001028570A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU78089/00A AU7808900A (en) 1999-10-20 2000-10-18 Zinc lactate lozenges and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9924677A GB2355405A (en) 1999-10-20 1999-10-20 Zinc lactate compositions
GB9924677.9 1999-10-20

Publications (2)

Publication Number Publication Date
WO2001028570A2 WO2001028570A2 (en) 2001-04-26
WO2001028570A3 true WO2001028570A3 (en) 2001-11-01

Family

ID=10862968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003990 Ceased WO2001028570A2 (en) 1999-10-20 2000-10-18 Zinc lactate lozenges and uses thereof

Country Status (3)

Country Link
AU (1) AU7808900A (en)
GB (1) GB2355405A (en)
WO (1) WO2001028570A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040151771A1 (en) 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
US20040180006A1 (en) * 2003-03-12 2004-09-16 Sceusa Nicholas A. Methods and compositions for blocking the calcium cascade
CN102614516A (en) * 2012-04-25 2012-08-01 黑龙江大学 Method for preparing odor-masking zinc lactate powder
US10058531B1 (en) 2017-06-01 2018-08-28 Spartak LLC Dosage delivery film

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503070A (en) * 1981-07-31 1985-03-05 Eby Iii George A Method for reducing the duration of the common cold
US5208031A (en) * 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
WO1998037859A1 (en) * 1997-02-28 1998-09-03 Fertin A/S An oral composition suitable for use in oral hygiene and dental care

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503070A (en) * 1981-07-31 1985-03-05 Eby Iii George A Method for reducing the duration of the common cold
US5208031A (en) * 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
WO1998037859A1 (en) * 1997-02-28 1998-09-03 Fertin A/S An oral composition suitable for use in oral hygiene and dental care

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GEIST, FELICIA C. ET AL: "In vitro activity of zinc salts against human rhinoviruses", ANTIMICROB. AGENTS CHEMOTHER. (1987), 31(4), 622-4, XP000998499 *

Also Published As

Publication number Publication date
WO2001028570A2 (en) 2001-04-26
GB2355405A (en) 2001-04-25
GB9924677D0 (en) 1999-12-22
AU7808900A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
CA2333375A1 (en) Sublingual buccal effervescent
SG170119A1 (en) Nutritional composition comprising indigestible oligosaccharides
CA2408142A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU1434000A (en) Nicotine-containing pharmaceutical compositions giving a rapid transmucosal absorption
EP1987821A3 (en) Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
CA2328730A1 (en) Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
CA2274910A1 (en) Flat medicament preparation for the application and release of buprenorphine or a pharmacologically comparable substance in the buccal cavity, and method of producing the same
MY122501A (en) Lactobacilli to increase absorption of minerals by intestinal cells
CA2532101A1 (en) Chewable antiplaque confectionery dental composition
JP2004520436A5 (en)
WO2003013549A3 (en) Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals
ES2052802T3 (en) PHARMACEUTICAL COMPOSITIONS SOLUBLE IN THE MOUTH CONTAINING ACETHYLCISTEINE.
PL367464A1 (en) Pharmaceutical composition comprising lumiracoxib
WO2001089536A3 (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
MXPA00003232A (en) Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects.
WO2001028570A3 (en) Zinc lactate lozenges and uses thereof
US6656920B2 (en) Composition and method for promoting oral health
WO2001026621A3 (en) Orally distintegrating composition comprising mirtazapine
CA2408633A1 (en) Management of snoring by oral administration of dimethyl sulfone
CA2399709A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
CA2578748C (en) Composition and method for prevention or treatment of stomatitis
WO2007056454A3 (en) Use of cicletanine and other furopyridines for treatment of hypertension
WO2002058707A3 (en) Method of treatment of type i diabetes with vitamin d compounds
EP1033133A4 (en) Composition for treatment of diabetes and treatment of diabetes
ATE428432T1 (en) ORAL PHARMACEUTICAL FORMULATION WITH ACTIVATED CHARCOAL AND USE THEREOF

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP